The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC announced the purchase and cancellation of 831,399 ordinary shares as part of its share buyback programme. This transaction is part of their strategy to manage their share capital and potentially enhance shareholder value. The buyback reduces the number of shares with voting rights to 9,034,076,586, which may impact shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. Its product portfolio includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements (VMS). The company is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum.
YTD Price Performance: 3.31%
Average Trading Volume: 27,838,266
Technical Sentiment Signal: Sell
Current Market Cap: £35.23B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.